Beijing Rosenbot Technology

About Beijing Rosenbot Technology

Beijing Rosenbot Technology, founded in 2017, is a specialized provider of robotic surgery solutions focusing on orthopedic procedures. The company is headquartered in Beijing's Haidian district, a major technology hub, and has expanded its presence to other Chinese cities including Shunde, Shanghai, and Wuhan. Rosenbot is committed to advancing the field of medical technology by developing systems that enhance the capabilities of surgeons.

The firm's core offering is a robotic surgical system designed for orthopedics, featuring real-time intraoperative 3D navigation, automatic surgical planning, and sophisticated fracture reduction operations. This technology aims to overcome the limitations often associated with minimally invasive surgery, providing surgeons with more precise and automated tools. Beyond its primary focus on surgical robotics, the company is also involved in the development and sale of industrial robot systems, robot body research and development, and hydrogen fuel cell equipment. A significant portion of the company's workforce, over 160 individuals, is dedicated to R&D, contributing to a portfolio of 168 intellectual property rights, including numerous patents for inventions and utility models.

From a financial perspective, Beijing Rosenbot Technology has demonstrated a strong ability to attract investment, securing a total of $14.3 million across four funding rounds. Its most recent capital infusion was a Series C round completed in January 2025. The company has garnered support from a diverse group of 13 institutional investors, which includes prominent firms such as Shenzhen Capital Group, Medtronic China Fund, and Alphax Partners. This consistent backing from the investment community underscores confidence in Rosenbot's market position and growth trajectory within the rapidly advancing medtech sector in China.